Charme Capital Partners
VC Fund
Milano, Italy
Charme Capital Partners is a European mid-market private equity fund, supporting management teams and shareholders to achieve transformational change, growth and internationalisationFrom our offices in Milan, London and Madrid we invest in businesses across Europe with an enterprise value of €100m to €500mContinuous interaction with ourinvestor base is key in sourcing new opportunities, testing investment theses and growing portfolio companies
- Total investments:
- 7
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries Charme Capital Partners invests in
Stages Charme Capital Partners invests in
Countries Charme Capital Partners invests in
Round sizes
Round size
- Series A
- $5.5M–$20M
Investment Focus
Industry
- Health Care 4 (57%)
- Medical 2 (29%)
- Medical Device 2 (29%)
- Health Diagnostics 2 (29%)
- Genetics 1 (14%)
Stage
- Private Equity 5 (71%)
- Series A 1 (14%)
Country
- Spain 3 (43%)
- Italy 2 (29%)
- United States 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
UNIVERSAE
|
UNIVERSAE offers vocational training services. | $32M / Private Equity / Apr 30, 2024 | |
Bianalisi
|
Bianalisi provides services that include toxicological examination of the hair, diagnostic imaging, specialised examinations, laboratory analysis, physiotherapy and rehabilitation, occupational medicine, and more. They offer diagnostic services. | Private Equity / Jan 01, 2021 | |
Tema Sinergie
|
Tema Sinergie provides diagnostic radiology, nuclear medicine, barrier isolation technology, radiotherapy, and industrial applications. | Private Equity / Jan 01, 2021 | |
Prism Healthcare
|
Prism Healthcare provides healthcare services and medical equipment through a group of different healthcare brands. | Private Equity / Jan 01, 2021 | |
INDIBA, S.A.
|
INDIBA, S.A is specialising in the design, manufacture and distribution of products and devices for use by medical, physiotherapy and beauty specialists. Our high-tech products and devices offer a non-invasive solution for the most common problems observed in the aesthetic medicine, plastic surgery, dermatology, sports medicine, physiotherapy andbeauty sectors.Some of our most important products and techniques include: Proionic® system, pulsed light, cryotherapy, cavitation and pressure therapy. We also developed the first radiofrequency for diathermy treatments. | Private Equity / Jan 01, 2021 | |
Veritas Intercontinental
|
The mission of Veritas Int. is to fulfill the promise of the human genome, empowering people to maximize the quality and length of life for themselves and their families. As the first company to introduce whole genome sequencing and interpretation to consumers and their physicians, we lead by relentlessly pushing the boundaries of science andtechnology while driving down the cost of the genome. Originally founded in 2014 by leaders in genomics from Harvard Medical School , Veritas Intercontinental was born in 2018 to deliver the promise of Whole Genome Sequencing outside United States. We have been recognized twice by MIT Technology Review as one of the 50 Smartest Companies in 2016 and 2017, by Fast Company as one of the world’s most innovative health companies in 2018, and by CNBC as one of the Disruptor 50 Companies in 2018. | $5.5M / Series A / Jul 05, 2020 | |
|
Veritas Intercontinental
|
The mission of Veritas Int. is to fulfill the promise of the human genome, empowering people to maximize the quality and length of life for themselves and their families. As the first company to introduce whole genome sequencing and interpretation to consumers and their physicians, we lead by relentlessly pushing the boundaries of science andtechnology while driving down the cost of the genome. Originally founded in 2014 by leaders in genomics from Harvard Medical School , Veritas Intercontinental was born in 2018 to deliver the promise of Whole Genome Sequencing outside United States. We have been recognized twice by MIT Technology Review as one of the 50 Smartest Companies in 2016 and 2017, by Fast Company as one of the world’s most innovative health companies in 2018, and by CNBC as one of the Disruptor 50 Companies in 2018. | $20M / Series A / Jul 14, 2018 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Charme Capital Partners invest in?
Charme Capital Partners invests primarily in Health Care, Medical and Medical Device startups, most often at Private Equity and Series A stage. Most of the 7 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Charme Capital Partners's check size?
Charme Capital Partners typically joins rounds of $5.5M–$20M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Charme Capital Partners participates in.
When did Charme Capital Partners last invest?
The most recent investment recorded for Charme Capital Partners closed in Apr 2024. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
